Goldline Pharmaceutical Limited (BOM:544759)
29.60
+0.33 (1.13%)
At close: Nov 16, 2026
Goldline Pharmaceutical Revenue
Goldline Pharmaceutical had revenue of 74.63M INR in the quarter ending September 30, 2026. In the fiscal year ending March 31, 2026, Goldline Pharmaceutical had annual revenue of 311.98M with 11.20% growth. That makes Goldline Pharmaceutical the 41,233rd largest company in the world by revenue and 4,107th in India.
Revenue
311.98M
Revenue Growth
+11.20%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
126
Market Cap
284.16M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 311.98M | 31.42M | 11.20% |
| Mar 31, 2025 | 280.56M | 44.90M | 19.05% |
| Mar 31, 2024 | 235.66M | 37.18M | 18.73% |
| Mar 31, 2023 | 198.48M | -41.62M | -17.33% |
| Mar 31, 2022 | 240.11M | 21.15M | 9.66% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Centuple Global | 5.62B |
| Dipna Pharmachem | 1.31B |
| Chandra Bhagat Pharma | 1.17B |
| VijayPD Ceutical | 1.00B |
| Medico Intercontinental | 864.77M |
| Medistep Healthcare | 731.36M |
| Zenlabs Ethica | 485.60M |
| Constronics Infra | 454.43M |